

Rozanolixizumab-noli (Rystiggo)



Provider Order Form rev. 10/04/2024

PATIENT INFORMATION

Referral Status: New Referral Updated Order Order Renewal

Patient Name:	DOB:	Patient Phone:
Patient Address:	Patient Email:	
Allergies:	<input type="checkbox"/> NKDA	Weight (lbs/kg): Height (in/cm):
Sex: <input type="checkbox"/> M / <input type="checkbox"/> F	Date of Last Infusion:	Next Due Date: Preferred Location:

DIAGNOSIS *(Please provide ICD-10 code in space provided)*

Generalized Myasthenia Gravis:
Other: Description:

REQUIRED INFORMATION

Start of last Rystiggo cycle: _____
Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 63 days from the start of the previous treatment cycle has not been established.

OTHER INFORMATION

- Weight <50kg:** Administer Rystiggo 420mg (3ml) subcutaneously every week for 6 weeks
- Weight 50kg - <100kg:** Administer Rystiggo 560mg (4ml) subcutaneously every week for 6 weeks
- Weight 100kg+:** Administer Rystiggo 840mg (6ml) subcutaneously every week for 6 weeks
- Administer as subcutaneous infusion using approved infusion pump at a rate of up to 20 mL/hour

ADDITIONAL ORDERS

LABORATORY ORDERS

- CBC at each dose every: _____
- CMP at each dose every: _____
- CRP at each dose every: _____
- Other: _____

PRE-MEDICATION ORDERS

- Tylenol 500mg / 650mg PO
- Loratadine 10mg PO
- Pepcid 20mg PO / IVP
- Benadryl 25mg / 50mg PO / IVP
- Solumedrol 40mg / 125mg IVP
- Other: _____

NURSING

- Hold infusion and notify provider for abnormal vital signs or signs/symptoms of infection or meningitis, new or worsening headache, or altered mental status
- Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-procedure observation

PROVIDER INFORMATION

Preferred Contact Name:	Preferred Contact Email:		
Ordering Provider:	Provider NPI:		
Referring Practice Name:	Phone:	Fax:	
Practice Address:	City:	State:	Zip Code:

REQUIRED DOCUMENTATION CHECKLIST *(Additional documentation required for processing and insurance approval)*

Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN including treatment failures or contraindications, MGFA Classification, MG-ADL Score
Required Labs: AChR antibody, MuSK antibodies, CRP, ESR

Provider Name *(print)* Provider Signature Date

Order valid for one year unless otherwise indicated. IV solutions/diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability.